Ganglioside GQ1b (bovine) sodium

Synonyms: ​Tetrasialoganglioside GQ1b sodium
Ganglioside GQ1b (Tetrasialoganglioside GQ1b) (bovine) sodium 是一种中枢和外周神经系统神经节苷脂,也是一种免疫刺激剂,可通过 ERK1/2、PKA、CREB、NR2A、NR2B 和 GSK3β 调控 NMDA 受体信号通路并上调 BDNF 表达,能够减轻 Aβ 病理改变、降低 tau 蛋白磷酸化水平及 APP 表达量,可用于阿尔茨海默病的相关研究。
产品编号: MS-Y31144 纯度: 98% CAS No.: 68652-37-9
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
100μg
询价
3-5 天
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

Ganglioside GQ1b (Tetrasialoganglioside GQ1b) (bovine) sodium 是一种中枢和外周神经系统神经节苷脂,也是一种免疫刺激剂,可通过 ERK1/2、PKA、CREB、NR2A、NR2B 和 GSK3β 调控 NMDA 受体信号通路并上调 BDNF 表达,能够减轻 Aβ 病理改变、降低 tau 蛋白磷酸化水平及 APP 表达量,可用于阿尔茨海默病的相关研究。

生物实验数据

生物活性 Ganglioside GQ1b (Tetrasialoganglioside GQ1b) (bovine) sodium is a ganglioside of the central and peripheral nervous systems and also an immunostimulant that regulates the NMDA receptor signaling pathway through ERK1/2, PKA, CREB, NR2A, NR2B, and GSK3β and upregulates BDNF expression, attenuates Aβ pathology, and reduces tau phosphorylation and APP expression, and can be used in research related to Alzheimer's disease.
IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

Ganglioside GQ1b (0.01-10 μM; 1-12 h) sodium 可呈时间依赖性上调 H19-7 大鼠海马细胞中 NMDA 受体亚基 NR2A 和 NR2B 的 mRNA 及蛋白表达。
Ganglioside GQ1b (0.01-10 μM; 12 h) sodium 可通过 NMDA 受体信号通路诱导 H19-7 大鼠海马细胞中 CREB 在 Ser-133 位点发生磷酸化。
Ganglioside GQ1b (1 μM; 12 h) sodium 可通过 NMDA 受体信号通路诱导 H19-7 大鼠海马细胞中 PKA、ERK1/2 和 CREB 的磷酸化。
Ganglioside GQ1b (0.001-1 μM; 1-24 h) sodium 可上调大鼠原代皮质神经元中 BDNF 的表达,并通过 BDNF/TrkB 信号通路恢复寡聚体 Aβ1-42 (MS-Q13835) 诱导的细胞死亡,同时还能逆转 Aβ 诱导的 BDNF 表达降低,且该过程不依赖于 TrkB 抑制。
Ganglioside GQ1b (0.01-10 μM; 1-24 h) sodium 可在 GQ1b 缺失型人神经母细胞瘤 SH-SY5Y 细胞中上调 BDNF mRNA 和蛋白的表达。
Ganglioside GQ1b (1 μM; 1-24 h) sodium 可通过 NMDA 受体信号通路上调大鼠原代皮质神经元中 BDNF 的 mRNA 及蛋白表达水平。
Ganglioside GQ1b (0.1-100 µmol/L; 1-6 days) sodium 可剂量依赖性地促进健康志愿者外周血单个核细胞 (PBMC) 自发产生 IgG、IgM 和 IgA,且不会改变 PBMC 的增殖能力。
Ganglioside GQ1b (0.01-100 µmol/L; 24 h) sodium 可特异性促进纯化人 T 细胞产生 IL-6 和 IL-10,但对人单核细胞、B 细胞的细胞因子产生,或外周血单个核细胞 (PBMC) 整体的 IL-1α、IL-1β、IL-2 及 IL-4 产生无影响。

RT-PCR

Cell Line: H19-7 rat hippocampal cells
Concentration: 0.01; 0.1; 1; 10 μM
Incubation Time: 1; 3; 6; 12 h
Result: Increased NR2A mRNA expression by 4.2-fold relative to control.
Increased NR2B mRNA expression by 5.9-fold relative to control.
Increased NR2A protein expression by 3.2-fold relative to control.
Increased NR2B protein expression by 4.3-fold relative to control.
Elevated mRNA expression of both subunits at 6 and 12 h, with the strongest effect at 12 h.
Identified 1 μM as the most effective concentration for inducing NR2A mRNA expression.

Western Blot Analysis

Cell Line: H19-7 rat hippocampal cells
Concentration: 0.01; 0.1; 1; 10 μM
Incubation Time: 12 h
Result: Increased pCREB levels significantly relative to control, with no change in total CREB expression.

Western Blot Analysis

Cell Line: H19-7 rat hippocampal cells
Concentration: 1 μM
Incubation Time: 30 min (pre-incubation); 12 h (incubation)
Result: Increased pPKA and pERK1/2 levels relative to control.

Real Time qPCR

Cell Line: GQ1b-null SH-SY5Y human neuroblastoma cells
Concentration: 0.01; 0.1; 1; 10 μM
Incubation Time: 1; 3; 6; 12; 24 h
Result: Increased BDNF mRNA expression most significantly at 1 μM for 12 h relative to vehicle.
Increased BDNF mRNA significantly as early as 1 h post-treatment with 1 μM GQ1b, with maximal effects between 9 and 15 h.
Increased BDNF protein levels significantly at 1 μM for 12 h and 24 h.
Increased BDNF protein expression significantly at 1 μM for 12 h via Western blotting, and co-treatment with 50 μM NeuAc2en did not alter this increase.
体内研究
(In Vivo)

Ganglioside GQ1b (1 μg;侧脑室注射;单次给药) sodium 可上调健康大鼠海马组织中 NMDA 受体亚基的表达,并激活 NMDA 受体信号通路。
Ganglioside GQ1b (1 μg;双侧海马内输注;每日 1 次;连续 7 天) sodium 可恢复老年 3xTg-AD 小鼠的认知功能。
Ganglioside GQ1b (1 µg;颅内注射;单次给药) sodium 可使大鼠前额叶皮层的 BDNF 表达水平升高 2.63 倍,海马体的 BDNF 表达水平升高 3.65 倍。

Animal Model: Sprague-Dawley rats (male, 7 weeks old)
Dosage: 1 μg
Administration: i.c.v.; single dose
Result: Increased NR2A mRNA and protein expression by 1.96-fold.
Increased NR2B mRNA and protein expression by 1.74-fold.
Increased NR2B Tyr1472 phosphorylation by 1.71-fold.
Increased ERK1/2 phosphorylation by 1.46-fold.
Increased PKA phosphorylation by 2.05-fold.
Increased CREB phosphorylation by 3.1-fold.
All changes were statistically significant compared to controls.
Animal Model: 3xTg-AD mice (18-22 months old); wild-type (age-matched)
Dosage: 1 μg
Administration: bilateral intrahippocampal infusion; once daily; 7 days
Result: Increased preferential index for novel object exploration to 68% in 3xTg-AD mice.
Increased interaction time with novel object to 14 s in 3xTg-AD mice.
Restored hippocampal BDNF protein levels to 86% of wild-type aCSF-treated levels.
Increased BDNF fluorescence intensity in CA3 region and dentate gyrus.
Increased hippocampal BDNF concentration.
Significantly increased phospho-TrkB levels compared to aCSF-infused 3xTg-AD mice.
Reduced Aβ plaque counts in CA3 region
Significantly decreased hippocampal Aβ oligomer levels, soluble Aβ1-42 and Aβ1-40 levels, and APP protein levels, while α-, β-, γ-secretase and Aβ-degrading enzyme levels remained unchanged.
Significantly reduced hippocampal phospho-tau levels at residues T181, T205, and T231 compared to aCSF-infused 3xTg-AD mice, while total tau levels remained unchanged.
Restored phospho-GSK3β levels, while PP2A levels remained unchanged.
Animal Model: Sprague-Dawley rats (male, 7-weeks-old)
Dosage: 1 µg
Administration: i.c.v.; single injection
Result: Increased BDNF protein expression 2.63-fold in the prefrontal cortex.
Increased BDNF protein expression 3.65-fold in the hippocampus.
性状 固体
颜色 White to off-white

化学信息

CAS No. 68652-37-9
别名 ​Tetrasialoganglioside GQ1b sodium

储存&溶解度

溶解度信息
Chloroform:Methanol (2:1): Soluble
H2O: Soluble
储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础